A Long-Term Extension (LTE) Study of Mavacamten
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; Registrational
- Acronyms Mava-LTE
- Sponsors MyoKardia
- 24 Oct 2018 According to a MyoKardia media release, the patient dosing has been started in this study. Up to 280 patients who successfully complete either MAVERICK-HCM or EXPLORER-HCM clinical trials will be eligible for enrollment in this study.
- 24 Oct 2018 Status changed from planning to recruiting, according to a MyoKardia media release.
- 17 Sep 2018 New trial record